Program
cilofexor
Also written as “Cilofexor”, “CILO” and “Cilofexor Dose B”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary, led by 2 companies.
Drug pageCilofexor: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 121 open or running | phase 3since Mar 25, 2019 | Jan 11, 2016 | Dec 2028phase 2 · NCT07841977 |
| Phenex Pharmaceuticals | 10 open or running | phase 2since Nov 19, 2013 | Nov 19, 2013 | none ahead |
Also a collaborator on its studies: Novo Nordisk.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Phenex Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Nov 19, 2013First study: phase 2 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT01999101 · 12 enrolled · Austria
- Dec 9, 2017Named cilofexorINNProposed as its International Nonproprietary Name in WHO's List 118
TargetBeta
“Bile acid receptor FXR agonist”ChEMBL 37, by rule
Other programs on NR1H4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| LY4395089 | Eli Lilly | phase 2 | 3 |
Studies
The one study Phenex Pharmaceuticals leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01999101Non-alcoholic Fatty Liver Disease · Austria | 2 | Completed | Jan 2015 | 12 |
How it is read
Names in the registry
- “Cilofexor”, 7 entries
- “CILO”, 2 entries
- “Cilofexor Dose B”, 1 entry
- “Cilofexor Dose A”, 1 entry
- “Cilofexor (CILO)/Firsocostat (FIR)”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 8 studies
- Cholangitis, Sclerosing, 3 studies
- Liver Cirrhosis, Biliary, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.